Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Maneesha Mehra"'
Autor:
Thomas Martin, Amrita Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 97-108 (2022)
Abstract Introduction Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell therapy that is being evaluated in the CARTITUDE‐1 trial (NCT03548207) in patients with relapsed or refractory multiple myeloma (RRMM) who r
Externí odkaz:
https://doaj.org/article/a405681420e34ef5b0861c5f9532c87e
Autor:
Rafael Fonseca, Saad Z. Usmani, Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Cote, Annette Lam, Jon Ukropec, Eric M. Maiese, Sandhya Nair, Ravi Potluri, Peter M. Voorhees
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities.
Externí odkaz:
https://doaj.org/article/0f1b33e8ad784fecbc53fa0b5af5dc8f
Autor:
Anthony Mato, Jordan Jahnke, Pengxiang Li, Maneesha Mehra, Vrushabh P. Ladage, Michelle Mahler, Scott Huntington, Jalpa A. Doshi
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
Externí odkaz:
https://doaj.org/article/b8a1f9385bde4f569d975d3305505fa3
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139440 (2015)
To identify patient populations most in need of treatment across the prostate cancer disease continuum, we developed a novel dynamic transition model based on risk of disease progression and mortality.We modeled the flow of patient populations throug
Externí odkaz:
https://doaj.org/article/6c05015de9604fdfbfd82d1bdca07257
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76882 (2013)
CONTEXT: Treatment Resistant Depression (TRD) is a significant and burdensome health concern. OBJECTIVE: To characterize, compare and understand the difference between TRD and non-TRD patients and episodes in respect of their episode duration, treatm
Externí odkaz:
https://doaj.org/article/b45485b83d2e40b6901b2a279c8b02a6
Autor:
Thomas Martin, Amrita Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsi Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath
Publikováno v:
eJHaem. 3:97-108
Ciltacabtagene autoleucel (cilta-cel) is a novel chimeric antigen receptor T-cell therapy that is being evaluated in the CARTITUDE-1 trial (NCT03548207) in patients with relapsed or refractory multiple myeloma (RRMM) who received as part of their pre
Autor:
Peter M. Voorhees, Jianming He, Sarah Cote, Ravi Potluri, Mary Slavcev, Annette Lam, Eric M Maiese, Maneesha Mehra, Sandhya Nair, Jon Ukropec, Rafael Fonseca, Saad Z. Usmani
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer
Background For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities. Here, we
Autor:
Maneesha Mehra, Bart Heeg, Joe Lawson, Olof Akre, Sabine Brookman-May, Mahmoud Hashim, Johan Liwing, Amy Leval, Markus Aly
Publikováno v:
European Urology Focus. 5:788-798
Context Until recently, there has been a lack of evidence-based treatment alternatives in men with nonmetastatic castrate-resistant prostate cancer (NM-CRPC). However, new evidence-based treatment alternatives are emerging. Objective We aimed to desc
Autor:
Andreas Pettersson, Tobias Nordström, Therese M.-L. Andersson, Sandra Eloranta, Amy Leval, Sandhya Nair, Frida Schain, Hari T Vigneswaran, Martin Eklund, Anna Warnqvist, L. Dearden, Markus Aly, Olof Akre, Maneesha Mehra, Johan Liwing
Publikováno v:
Scandinavian journal of urology. 55(4)
Background Studies describing treatment utilization for castration-resistant prostate cancer (CRPC) are limited. We aimed to describe the treatment utilization of a contemporary population-based CRPC cohort between 2006 and 2016. Methods We identifie
Autor:
Lin Li, Yunan Li, Anandaroop Dasgupta, Paul Zeltzer, Lugui Qiu, Rian Van Rampelbergh, Ravi Potluri, Qing Li, Jianming He, Peter Hu, Ute Richarz, Sepideh Nemat, Maneesha Mehra, Luke M. Schmerold, Steven S. Smugar, Carlos Appiani
Publikováno v:
Advances in Therapy
Introduction The objective of this study was to describe the treatment patterns among patients with newly diagnosed multiple myeloma (MM) who had not received autologous stem cell transplantation (ASCT). It further compares the safety and clinical ou